Alterity Therapeutics Files May 2026 Form 6-K, Releases New Corporate Presentation

Alterity Therapeutics ( (ATHE) ) has shared an update.

On May 12, 2026, Alterity Therapeutics filed a Form 6-K with the U.S. Securities and Exchange Commission for the month of May as a foreign private issuer. The filing incorporates certain existing registration statements by reference and primarily serves to furnish investors with the company’s May 2026 corporate presentation, underscoring ongoing disclosure and engagement with capital markets.

The report, signed by Chairman Julian Babarczy, formalizes the submission of the updated corporate materials under SEC rules. While the content of the presentation is not detailed in the filing, the move signals continued transparency regarding Alterity’s development-stage activities and supports its compliance obligations for U.S. investors and regulators.

The most recent analyst rating on (ATHE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the ATHE Stock Forecast page.

Spark’s Take on ATHE Stock

According to Spark, TipRanks’ AI Analyst, ATHE is a Neutral.

The score is held down primarily by weak financial performance (ongoing losses and negative cash flows) and loss-driven valuation (negative P/E). Technicals provide partial support due to a strong uptrend, but overbought momentum signals temper the overall rating.

To see Spark’s full report on ATHE stock, click here.

More about Alterity Therapeutics

Alterity Therapeutics Limited is an Australia-based development-stage biopharmaceutical company focused on therapeutic research and development. The company operates from Melbourne and is listed in the U.S. as a foreign private issuer under the Securities Exchange Act.

Average Trading Volume: 17,217

Technical Sentiment Signal: Buy

Current Market Cap: $86.52M

For detailed information about ATHE stock, go to TipRanks’ Stock Analysis page.